Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Blood|October 18, 2008
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivoLeandro C Cerchietti, Shao Ning Yang, Rita Shaknovich, et al.
Biomaterials|September 26, 2015
Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cellsYe F Tian, Haelee Ahn, Rebecca S Schneider, et al.
Oncotarget|December 15, 2015
Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphomaThibault Dupont, Shao Ning Yang, Jayeshkumar Patel, et al.
Plos One|April 16, 2011
Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomasLeandro Cerchietti, Christine Damm-Welk, Inga Vater, et al.
Clinical Epigenetics|July 26, 2016
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patientsBenet Pera, Tiffany Tang, Rossella Marullo, et al.
Blood|May 2, 2013
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytesJia Ruan, Min Luo, Chunjie Wang, et al.
The Journal of Clinical Investigation|November 4, 2015
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphomaRebecca L Goldstein, Shao Ning Yang, Tony Taldone, et al.
Blood|March 25, 2009
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCLWeimin Ci, Jose M Polo, Leandro Cerchietti, et al.
Oncotarget|October 30, 2016
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypesMichela Boi, Maria Todaro, Valentina Vurchio, et al.
Nature Medicine|December 8, 2009
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomasLeandro C Cerchietti, Eloisi C Lopes, Shao Ning Yang, et al.
Pageof 3